During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...
DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...
AnHeart describes taletrectinib as a “next-generation” ROS1 inhibitor that could improve on other drugs in the class, like Pfizer’s first-to-market Xalkori (crizotinib), for example ...
About 1% to 2% of NSCLCs have the ROS1 mutation. The ROS1 mutation is similar to the ALK mutation. Some of the same drugs help treat both mutations. Targeted therapies for ROS1-positive lung ...
The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth quarter and full year ended ...
accepted and granted Priority Review to the New Drug Application (NDA) for taletrectinib for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC); Prescription Drug User Fee Act ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback